 NEW YORK, Sept. 30, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX, today announced the submission of a Biologics License Application BLA to the U.S. Food and Drug Administration FDA requesting approval of ublituximab, the Companys investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis RMS. The submission was based on the results of the ULTIMATE I II trials, two identical Phase 3, randomized, global, multi-center, double-blinded, active-controlled trials evaluating ublituximab compared to teriflunomide in patients with RMS. The ULTIMATE I II trials were conducted under a Special Protocol Assessment SPA agreement with the FDA. 